Summary | |
---|---|
Symbol | PIAS3 |
Name | protein inhibitor of activated STAT, 3 |
Aliases | FLJ14651; ZMIZ5; zinc finger, MIZ-type containing 5; protein inhibitor of activated STAT protein 3; E3 SUMO- ...... |
Chromosomal Location | 1q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cytoplasm Nucleus Nucleus speckle Note=Colocalizes with MITF in the nucleus. Colocalizes with GFI1 in nuclear dots. Colocalizes with SUMO1 in nuclear granules. |
Domain |
PF14324 PINIT domain PF02891 MIZ/SP-RING zinc finger |
Function |
Functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor. Plays a crucial role as a transcriptional coregulation in various cellular pathways, including the STAT pathway and the steroid hormone signaling pathway. Involved in regulating STAT3 signaling via inhibiting STAT3 DNA-binding and suppressing cell growth. Enhances the sumoylation of MTA1 and may participate in its paralog-selective sumoylation (PubMed:21965678, PubMed:9388184). Sumoylates CCAR2 which promotes its interaction with SIRT1 (PubMed:25406032). Diminishes the sumoylation of ZFHX3 by preventing the colocalization of ZFHX3 with SUMO1 in the nucleus (PubMed:24651376). |
Biological Process |
GO:0016925 protein sumoylation GO:0018205 peptidyl-lysine modification GO:0033233 regulation of protein sumoylation GO:0033234 negative regulation of protein sumoylation GO:0033235 positive regulation of protein sumoylation GO:0042391 regulation of membrane potential GO:0045838 positive regulation of membrane potential GO:1903320 regulation of protein modification by small protein conjugation or removal GO:1903321 negative regulation of protein modification by small protein conjugation or removal GO:1903322 positive regulation of protein modification by small protein conjugation or removal |
Molecular Function |
GO:0008022 protein C-terminus binding GO:0015459 potassium channel regulator activity GO:0016247 channel regulator activity GO:0016874 ligase activity GO:0019787 ubiquitin-like protein transferase activity GO:0019789 SUMO transferase activity GO:0047485 protein N-terminus binding |
Cellular Component |
GO:0016604 nuclear body GO:0016607 nuclear speck GO:0030425 dendrite |
KEGG |
hsa04120 Ubiquitin mediated proteolysis hsa04630 Jak-STAT signaling pathway |
Reactome |
R-HSA-73894: DNA Repair R-HSA-5696395: Formation of Incision Complex in GG-NER R-HSA-5696399: Global Genome Nucleotide Excision Repair (GG-NER) R-HSA-392499: Metabolism of proteins R-HSA-5696398: Nucleotide Excision Repair R-HSA-597592: Post-translational protein modification R-HSA-3108232: SUMO E3 ligases SUMOylate target proteins R-HSA-2990846: SUMOylation R-HSA-4615885: SUMOylation of DNA replication proteins R-HSA-3232118: SUMOylation of transcription factors |
Summary | |
---|---|
Symbol | PIAS3 |
Name | protein inhibitor of activated STAT, 3 |
Aliases | FLJ14651; ZMIZ5; zinc finger, MIZ-type containing 5; protein inhibitor of activated STAT protein 3; E3 SUMO- ...... |
Chromosomal Location | 1q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between PIAS3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between PIAS3 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | PIAS3 |
Name | protein inhibitor of activated STAT, 3 |
Aliases | FLJ14651; ZMIZ5; zinc finger, MIZ-type containing 5; protein inhibitor of activated STAT protein 3; E3 SUMO- ...... |
Chromosomal Location | 1q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of PIAS3 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | PIAS3 |
Name | protein inhibitor of activated STAT, 3 |
Aliases | FLJ14651; ZMIZ5; zinc finger, MIZ-type containing 5; protein inhibitor of activated STAT protein 3; E3 SUMO- ...... |
Chromosomal Location | 1q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of PIAS3 in various data sets.
|
Points in the above scatter plot represent the mutation difference of PIAS3 in various data sets.
|
Summary | |
---|---|
Symbol | PIAS3 |
Name | protein inhibitor of activated STAT, 3 |
Aliases | FLJ14651; ZMIZ5; zinc finger, MIZ-type containing 5; protein inhibitor of activated STAT protein 3; E3 SUMO- ...... |
Chromosomal Location | 1q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PIAS3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | PIAS3 |
Name | protein inhibitor of activated STAT, 3 |
Aliases | FLJ14651; ZMIZ5; zinc finger, MIZ-type containing 5; protein inhibitor of activated STAT protein 3; E3 SUMO- ...... |
Chromosomal Location | 1q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PIAS3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PIAS3. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | PIAS3 |
Name | protein inhibitor of activated STAT, 3 |
Aliases | FLJ14651; ZMIZ5; zinc finger, MIZ-type containing 5; protein inhibitor of activated STAT protein 3; E3 SUMO- ...... |
Chromosomal Location | 1q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PIAS3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | PIAS3 |
Name | protein inhibitor of activated STAT, 3 |
Aliases | FLJ14651; ZMIZ5; zinc finger, MIZ-type containing 5; protein inhibitor of activated STAT protein 3; E3 SUMO- ...... |
Chromosomal Location | 1q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of PIAS3 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | PIAS3 |
Name | protein inhibitor of activated STAT, 3 |
Aliases | FLJ14651; ZMIZ5; zinc finger, MIZ-type containing 5; protein inhibitor of activated STAT protein 3; E3 SUMO- ...... |
Chromosomal Location | 1q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between PIAS3 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | PIAS3 |
Name | protein inhibitor of activated STAT, 3 |
Aliases | FLJ14651; ZMIZ5; zinc finger, MIZ-type containing 5; protein inhibitor of activated STAT protein 3; E3 SUMO- ...... |
Chromosomal Location | 1q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting PIAS3 collected from DrugBank database. |
There is no record. |